As the rate of corporate-owned healthcare practices rise, providers say a lack of autonomy leads to diminished patient care.
Corporate healthcare ownership reduces care quality, physician survey finds Read More »
The name change comes nearly two years after the merger between the health systems closed.
Chicago-area NorthShore – Edward-Elmhurst rebrands to Endeavor Health Read More »
The for-profit operator said low reimbursement rates and financial challenges will cause it to shutter the 182-bed facility.
Steward Health Care to close Massachusetts hospital amid financial troubles Read More »
El dolor cervical es una condición que afecta a millones de personas en todo el mundo, manifestándose como molestias, rigidez y tensión en la zona del cuello. Este problema puede derivar de diversas causas, desde malas posturas hasta lesiones, estrés crónico o enfe …
¿Cómo dormir con dolor cervical? Consejos y trucos para un sueño reparador Read More »
VitriVax, Inc ., a formulation technology company, announced today a $5M two-year grant from the Bill & Melinda Gates Foundation.
VitriVax Receives $5M Grant for Vaccine Development Read More »
Syros Pharmaceuticals today announced strong and encouraging initial data from its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective, retinoic acid receptor alpha (RARα) agonist.
Abcuro, Inc. today announced the appointment of Mark Pruzanski, M.D., as Chairman of its Board of Directors.
Abcuro Appoints Mark Pruzanski, M.D., as Chairman of its Board of Directors Read More »
Marengo Therapeutics, Inc. today announced that its lead program, STAR0602, is the subject of an article published in the latest edition of Science Translational Medicine.
NAYA Biosciences and ONK Therapeutics to assess proof-of-concept and establish activity and feasibility of the combination of NAYA’s FLEX-NK™ bispecific antibodies.
Dr. Reddy’s Laboratories SA and Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya”), today announced that they have entered into a development and license agreement (the “Agreement”) for the development and commercialization of COYA 302.
